SCHEMBL5582220

SCHEMBL5582220

CNc1ncc2c(-c3cccc(Cl)c3Cl)ccc(OC)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.39
KDM4E B2RXH2 2/20 0.38
NUDT1 P36639 3/20 0.37
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
SRC P12931 2/20 0.36
EGFR P00533 2/20 0.36
FGFR1 P11362 2/20 0.36
EPHB4 P54760 1/20 0.36
CRHR1 P34998 1/20 0.36
CCR4 P51679 1/20 0.35
AXL P30530 1/20 0.35
TYRO3 Q06418 1/20 0.35
MERTK Q12866 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPN11 Q06124 1/20 0.35
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5582236 0.90 LRRK2 (0.43) LRRK2EGFRFGFR1CRHR1AXL
SCHEMBL5581909 0.81 ALDH1A1 (0.46) LRRK2KDM4ESRCCRHR1ALDH1A1
SCHEMBL5582307 0.80 PDE4B (0.41) NUDT1JAK2JAK1ALDH1A1MAPT
SCHEMBL5582213 0.80 EGFR (0.38) LRRK2NUDT1PDCD1CD274SRC
SCHEMBL5581786 0.79 ALDH1A1 (0.41) LRRK2EGFRTYRO3MERTKJAK2
SCHEMBL5582243 0.79 IDO1 (0.42) EGFRAXLTYRO3MERTKKMT2A
SCHEMBL5581811 0.79 PDGFRB (0.43) LRRK2ALDH1A1
SCHEMBL5582334 0.78 ALDH1A1 (0.40) LRRK2CRHR1ALDH1A1
SCHEMBL5582323 0.76 PDGFRB (0.42) LRRK2CCR4AXLTYRO3MERTK
SCHEMBL5581749 0.76 FYN (0.43) EGFREPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 LRRK2 176/4885KDM4E 1708/4885NUDT1 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.